When Roche looks at China, it sees opportunities to access innovative technologies and leverage the expertise of very talented scientists, as well as opportunities to bring world-class drugs to a huge population with a growing demand for Western-style medicines. Read more »
“In China, unless you have deep resources, it is difficult to come and do everything yourself,” said Greg Scott of ChinaBio®. “The market is fragmented, distribution is complex, and drug approval and pricing are complicated. It may take longer than in the West to bring a product to market, and business is conducted differently.” Read more »
“Chinese investors haven’t lost a lot of money in biotech, so they’re in a good mood.” In the West, venture capital is drying up for life science firms so some small companies have come to Asia to raise financing where there is an available supply of money. Read more »
“Our vision is to create platforms so that anyone who wants to explore an idea can come and use the platform in their most effective way to push their idea and innovation. We are always being asked, ‘Why don’t you become a pharma company?’ But that’s not who we are. For us, it’s about being able to enable innovation across the board. We think it’s a very important mission.” Read more »
Everything has changed in partnering on both sides of the table except the necessary tension for negotiating a good deal. Yet if the relations between VCs and pharma executives are strained, they still can’t get enough of each other. Read more »
A mix of novel science and bold selling strategies won the big bio-bucks and stole headlines as top deals over the past year. A few of the winners shared their secrets in this panel session at BIO-Europe Spring® 2013. Read more »
The last year in biotech saw a breakout from prior performance on multiple fronts across stocks, drug approvals, venture returns, and pharma investing. Read more »
Is the value in translational research and preclinical programs to be found in the science or the people who are carrying forward a potential breakthrough? Three executives on the front lines of investing offer surprising insights. Read more »
Hot Companies
Newsletter
